Annexin Pharmaceuticals AB (ANNX) — Cash Flow-to-Debt Ratio
Annexin Pharmaceuticals AB (ANNX) has a Cash Flow-to-Debt Ratio of -1.86x as of March 2026, meaning its operating cash flow of Skr-10.33 Million could theoretically repay -2% of its total liabilities (Skr5.56 Million) in one year. See ANNX current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Annexin Pharmaceuticals AB Cash Flow-to-Debt Ratio (2015–2025)
Historical debt coverage capacity for Annexin Pharmaceuticals AB across 11 annual periods. Also explore Annexin Pharmaceuticals AB equity growth rate to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Annexin Pharmaceuticals AB (2015–2025)
Year-by-year debt coverage analysis for Annexin Pharmaceuticals AB. For market capitalisation and broader financial context, see Annexin Pharmaceuticals AB market cap and net worth.
| Year | CF-to-Debt Ratio | Operating CF (SEK) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -7.07x | Skr-36.92 Million | Skr5.22 Million | ▲ +25.1% |
| 2024 | -9.44x | Skr-50.23 Million | Skr5.32 Million | ▼ -72.8% |
| 2023 | -5.46x | Skr-43.40 Million | Skr7.95 Million | ▲ +13.4% |
| 2022 | -6.31x | Skr-41.16 Million | Skr6.53 Million | ▲ +15.1% |
| 2021 | -7.43x | Skr-45.02 Million | Skr6.06 Million | ▲ +14.3% |
| 2020 | -8.67x | Skr-39.20 Million | Skr4.52 Million | ▼ -53.3% |
| 2019 | -5.66x | Skr-25.73 Million | Skr4.55 Million | ▼ -22.8% |
| 2018 | -4.61x | Skr-28.50 Million | Skr6.19 Million | ▲ +24.5% |
| 2017 | -6.10x | Skr-39.08 Million | Skr6.41 Million | ▼ -383.3% |
| 2016 | -1.26x | Skr-9.95 Million | Skr7.88 Million | ▲ +17.4% |
| 2015 | -1.53x | Skr-5.01 Million | Skr3.28 Million | — |